Sugammadex in a Patient with Brugada Syndrome

Brugada Syndrome was first described in 1992 by Pedro Brugada as a genetic syndrome that is characterized by ventricular arrhythmias that may result in sudden cardiac arrest. In particular, a right bundle branch block and ST segment elevation in the right precordial leads are observed. Many perioper...

Full description

Saved in:
Bibliographic Details
Published inTurkish Journal of Anaesthesiology and Reanimation Vol. 44; no. 2; pp. 99 - 101
Main Authors Biricik, Ebru, Hatipoğlu, Zehra, Küçükbingöz, Çağatay
Format Journal Article
LanguageEnglish
Published Turkey Turkish Anaesthesiology and Intensive Care Society 01.04.2016
Subjects
Case Report
sugammadex
Brugada Syndrome
anaesthesia
Online AccessGet full text

Cover

More Information
Summary:Brugada Syndrome was first described in 1992 by Pedro Brugada as a genetic syndrome that is characterized by ventricular arrhythmias that may result in sudden cardiac arrest. In particular, a right bundle branch block and ST segment elevation in the right precordial leads are observed. Many perioperative pharmalogical and physiological factors can trigger malignant arrhythmias. Although it is a rare condition, the anaesthestic management of Brugada syndrome is important because of the potentially fatal complications. Many anaesthetics have been administered during the operation of patients with Brugada Syndrome. The use of sugammadex instead of the anaesthetic management of patients with Brugada syndrome is discussed in this study.
ISSN:2149-0937
2149-276X
DOI:10.5152/TJAR.2016.60973